Shandong Pharmaceutical Glass Co Ltd
SSE:600529
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Shandong Pharmaceutical Glass Co Ltd
Cash from Operating Activities
Shandong Pharmaceutical Glass Co Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Shandong Pharmaceutical Glass Co Ltd
SSE:600529
|
Cash from Operating Activities
¥576.9m
|
CAGR 3-Years
32%
|
CAGR 5-Years
0%
|
CAGR 10-Years
4%
|
|
|
S
|
Shanghai Conant Optical Co Ltd
HKEX:2276
|
Cash from Operating Activities
¥477.8m
|
CAGR 3-Years
37%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Autobio Diagnostics Co Ltd
SSE:603658
|
Cash from Operating Activities
¥1.3B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Winner Medical Co Ltd
SZSE:300888
|
Cash from Operating Activities
¥1.3B
|
CAGR 3-Years
13%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
Cash from Operating Activities
¥1.4B
|
CAGR 3-Years
21%
|
CAGR 5-Years
10%
|
CAGR 10-Years
19%
|
|
|
Intco Medical Technology Co Ltd
SZSE:300677
|
Cash from Operating Activities
¥1.7B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
Shandong Pharmaceutical Glass Co Ltd
Glance View
In the vast landscape of China's industrial might lies Shandong Pharmaceutical Glass Co Ltd., a company serving as a key player in the healthcare and pharmaceutical sectors. Established in 1970, the company has developed a reputation as a leading manufacturer and supplier of pharmaceutical packaging, particularly glass containers. It specializes in producing molded glass and glass tubing that form the backbone of safe and reliable drug delivery systems, including ampoules, vials, and cartridges. Over the decades, Shandong Pharmaceutical Glass Co Ltd. has leveraged its expertise in glass manufacturing to meet stringent industry standards and cater to the ever-evolving needs of its clients, ranging from pharmaceutical giants to smaller biotech firms. At the heart of its business model, Shandong Pharmaceutical Glass generates revenue by providing essential packaging solutions that are integral to the pharmaceutical supply chain. The company's success hinges on its ability to innovate and produce high-quality, durable glass products that ensure the integrity and safety of medicinal products during storage, transportation, and administration. With the rising global demand for pharmaceuticals, particularly in Asia Pacific markets, Shandong Pharmaceutical Glass's focus on sustainable, efficient, and technologically advanced manufacturing processes positions it strategically to capitalize on growth opportunities. By embedding itself in the pharmaceutical lifecycle, the company not only safeguards medications but also fortifies its own standing in a rapidly expanding industry.
See Also
What is Shandong Pharmaceutical Glass Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
576.9m
CNY
Based on the financial report for Dec 31, 2025, Shandong Pharmaceutical Glass Co Ltd's Cash from Operating Activities amounts to 576.9m CNY.
What is Shandong Pharmaceutical Glass Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
4%
Over the last year, the Cash from Operating Activities growth was -50%. The average annual Cash from Operating Activities growth rates for Shandong Pharmaceutical Glass Co Ltd have been 32% over the past three years , and 4% over the past ten years .